1-4 of 4
Mark Walsh
Close
Sort by
Journal Articles

Cladribine, Cytarabine, Granulocyte Colony Stimulating Factor ± Mitoxantrone (CLAG ± M) Is Highly Effective Therapy for Secondary and Relapsed/Refractory Acute Myeloid Leukemia

Amanda Przespolewski, DO, Craig W. Freyer, PharmD, Wenyan Ji, MA, Tara L. Cronin, BA, Swapna Thota, MD, Elizabeth A. Griffiths, MD, James E. Thompson, MD, Amro Elshoury, MBBChir, Jeffrey Baron, PharmD, Mark Walsh, PharmD, Eunice S. Wang, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1361.
https://doi.org/10.1182/blood-2019-130582
Published: 2019
Journal Articles

Rate of Venous Thromboembolism in Obese Patients Undergoing General Surgery: A Retrospective Cohort Study

Andrea Meade, BSc. Pharm, ACPR, Sudeep Shivakumar, MDFRCPC, Susan Bowles, BSc. Pharm, PharmD, MSc, Mark Walsh, MSc, MD FRCSC, Michael MacNeil, PharmD, ACPR
Journal: Blood
Blood (2014) 124 (21): 4261.
https://doi.org/10.1182/blood.V124.21.4261.4261
Published: 2014
Journal Articles

An accompanying genetic severe deficiency of tissue factor protects mice with a protein C deficiency from lethal endotoxemia

Francis J. Castellino, Deborah L. Donahue, Rudolph M. Navari, Victoria A. Ploplis, Mark Walsh
Journal: Blood
Blood (2011) 117 (1): 283–289.
https://doi.org/10.1182/blood-2010-07-299057
Published: 2011
Journal Articles

Classification of Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) According to the Han's Criteria Defines Two Groups of Patients with Different Clinical Outcomes Following Systemic Rituximab-Multi Agent Anthracycline-Based Therapy.

Julio Chavez, MD, Mark Walsh, Pharm, D, Francisco J Hernandez-Ilizaliturri, MD, Anjana Elefante, Pharm, D, Myron S. Czuczman, MD
Journal: Blood
Blood (2009) 114 (22): 623.
https://doi.org/10.1182/blood.V114.22.623.623
Published: 2009